Cargando…

Pulmonary vasodilation by sildenafil in acute intermediate-high risk pulmonary embolism: a randomized explorative trial

BACKGROUND: To investigate if acute pulmonary vasodilation by sildenafil improves right ventricular function in patients with acute intermediate-high risk pulmonary embolism (PE). METHODS: Single center, explorative trial. Patients with PE were randomized to a single oral dose of sildenafil 50 mg (n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andersen, Asger, Waziri, Farhad, Schultz, Jacob Gammelgaard, Holmboe, Sarah, Becker, Søren Warberg, Jensen, Tage, Søndergaard, Hanne Maare, Dodt, Karen Kaae, May, Ole, Mortensen, Ulrik Markus, Kim, Won Yong, Mellemkjær, Søren, Nielsen-Kudsk, Jens Erik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7916297/ https://www.ncbi.nlm.nih.gov/pubmed/33639897 http://dx.doi.org/10.1186/s12890-021-01440-7

Ejemplares similares

Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences
por: Andersen, Asger, et al.
Publicado: (2017)

Pulmonary vasodilation in acute pulmonary embolism – a systematic review
por: Lyhne, Mads Dam, et al.
Publicado: (2020)

Putative Biomarkers for Acute Pulmonary Embolism in Exhaled Breath Condensate
por: Gade, Inger Lise, et al.
Publicado: (2021)

Accelerated Rule-Out of acute Myocardial Infarction using prehospital copeptin and in-hospital troponin: The AROMI study
por: Pedersen, Claus Kjær, et al.
Publicado: (2023)

Apelin and pulmonary hypertension
por: Andersen, Charlotte U., et al.
Publicado: (2011)

Chest pain in the ambulance; prevalence, causes and outcome - a retrospective cohort study
por: Pedersen, Claus Kjær, et al.
Publicado: (2019)

Comparison of intravenous sildenafil with inhaled nitric oxide for acute vasodilator testing in pulmonary arterial hypertension
por: Kumar, Shine, et al.
Publicado: (2022)

Reverse remodeling of tricuspid valve morphology and function in chronic thromboembolic pulmonary hypertension patients following pulmonary thromboendarterectomy: a cardiac magnetic resonance imaging and invasive hemodynamic study
por: Frederiksen, Christian Alcaraz, et al.
Publicado: (2021)

Dyspnea, a high-risk symptom in patients suspected of myocardial infarction in the ambulance? A population-based follow-up study
por: Bøtker, Morten Thingemann, et al.
Publicado: (2016)

Persistent Pulmonary Hypertension of the Newborn: The Efficacy Comparison of Vasodilators Sildenafil Plus Bosentan Versus Sildenafil Plus Beraprost at a Tertiary Childcare Health Facility
por: Adnan, Mudasser, et al.
Publicado: (2021)

Association of residual pulmonary hypertension with survival after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension
por: Kallonen, Janica, et al.
Publicado: (2022)

Balloon pulmonary angioplasty for patients with chronic thromboembolic pulmonary hypertension previously operated by pulmonary endarterectomy
por: Andersen, Asger, et al.
Publicado: (2022)

Sex and survival following pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension: a Scandinavian observational cohort study
por: Kallonen, Janica, et al.
Publicado: (2021)

Sildenafil in the treatment of pulmonary hypertension
por: Barnett, Christopher F, et al.
Publicado: (2006)

Comment on “Effect of Riociguat and Sildenafil on Right Heart Remodeling and Function in Pressure Overload Induced Model of Pulmonary Arterial Banding”
por: Andersen, Asger
Publicado: (2018)

Adenosine as pulmonary vasodilator in ARDS
por: Molina, JM, et al.
Publicado: (1998)

A porcine in-vivo model of acute pulmonary embolism
por: Schultz, Jacob, et al.
Publicado: (2017)

Pulmonary artery stent for bronchial adenoid cystic carcinoma causing pulmonary artery stenosis
por: Smith, Corey Allister, et al.
Publicado: (2014)

Levosimendan in pulmonary hypertension and right heart failure
por: Hansen, Mona Sahlholdt, et al.
Publicado: (2018)

Sildenafil in pediatric pulmonary arterial hypertension
por: Dhariwal, AK, et al.
Publicado: (2015)

Inhaled pulmonary vasodilators in refractory hypoxemia
por: Wright, Brian J.
Publicado: (2015)

Levosimendan, milrinone, and dobutamine in experimental acute pulmonary embolism
por: Lyhne, Mads D., et al.
Publicado: (2021)

Pulmonary Artery Occlusion and Mediastinal Fibrosis in a Patient on Dopamine Agonist Treatment for Hyperprolactinemia
por: Su, Junjing, et al.
Publicado: (2017)

Effectiveness of pulmonary vasodilators on pulmonary hypertension associated with POEMS syndrome
por: Ohashi, Kana, et al.
Publicado: (2019)

Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil‐Bosentan and Sildenafil‐Ambrisentan Combination Therapies for Pulmonary Hypertension
por: Hakamata, A, et al.
Publicado: (2016)

Wave Intensity Analysis Provides Novel Insights Into Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
por: Su, Junjing, et al.
Publicado: (2017)

Pulmonary arterial size and response to sildenafil in chronic thromboembolic pulmonary hypertension
por: Toshner, Mark R., et al.
Publicado: (2010)

Oxygen-Sensitivity and Pulmonary Selectivity of Vasodilators as Potential Drugs for Pulmonary Hypertension
por: Morales-Cano, Daniel, et al.
Publicado: (2021)

Efficacy and safety of oral pulmonary vasodilators in pulmonary veno‐occlusive disease
por: Nakamura, Junichi, et al.
Publicado: (2022)

A multicentre, randomized, controlled open-label trial to compare an Accelerated Rule-Out protocol using combined prehospital copeptin and in-hospital high sensitive troponin with standard rule-out in patients suspected of acute Myocardial Infarction – the AROMI trial
por: Pedersen, Claus Kjær, et al.
Publicado: (2018)

Improvement of pulmonary arterial compliance by pulmonary vasodilator in pulmonary hypertension from combined pulmonary fibrosis and emphysema
por: Kusaka, Kei, et al.
Publicado: (2019)

NT-proBNP <95 ng/l can exclude pulmonary hypertension on echocardiography at diagnostic workup in patients with interstitial lung disease
por: Andersen, Charlotte, et al.
Publicado: (2016)

Is Sildenafil an Effective Therapy in the Management of Persistent Pulmonary Hypertension?
por: Yaseen, Hakam, et al.
Publicado: (2012)

Bosentan and sildenafil in the treatment of HIV-associated pulmonary hypertension
por: Chinello, Pierangelo, et al.
Publicado: (2011)

Sildenafil in endotoxin-induced pulmonary hypertension: an experimental study
por: Kemper, Daniella Aparecida Godoi, et al.
Publicado: (2021)

Effects of Different Pulmonary Vasodilators on Arterial Saturation in a Model of Pulmonary Hypertension
por: Becker, Eva Maria, et al.
Publicado: (2013)

Pulmonary vasodilators: beyond the bounds of pulmonary arterial hypertension therapy in COVID-19
por: Franco, Veronica, et al.
Publicado: (2020)

Efficacy, safety and tolerability of bosentan as an adjuvant to sildenafil and sildenafil alone in persistant pulmonary hypertension of newborn (PPHN)
por: Vijay Kumar, J.R., et al.
Publicado: (2021)

It’s Time to Put the Term “Pulmonary Vasodilators” to Rest
por: Rubin, Lewis J.
Publicado: (2021)

Selective Use of Pulmonary Vasodilators in Patients with Fontan Physiology
por: Glenn, Thomas, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7u6m3j8eg1k8bpcrd7i60jmodv